What is Enterome?
Enterome is at the forefront of biopharmaceutical innovation, specializing in the development of breakthrough immunomodulatory drugs. The company's core strength lies in its proprietary bacterial Mimicry drug discovery platform, which enables the identification of novel biological insights from the vast proteome of gut bacteria. This unique approach allows Enterome to uncover potentially first-in-class small protein and peptide drug candidates designed to modulate the immune system by mimicking specific biological signals. The company's focus areas include the treatment of cancer and immune diseases, positioning it as a key player in the rapidly evolving field of microbiome-based therapeutics.
How much funding has Enterome raised?
Enterome has raised a total of $145.4M across 6 funding rounds:
Series A
$5M
Series B
$13.8M
Series C
$16.4M
Series D
$38.5M
Series E
$52.6M
Other Financing Round
$19M
Series A (2012): $5M with participation from Lundbeckfond Ventures and Seventure Partners
Series B (2014): $13.8M led by Lundbeckfond Ventures, Omnes Capital, and Seventure Partners
Series C (2016): $16.4M supported by Lundbeckfond Ventures, Nestlé Health Science, and Seventure Partners
Series D (2018): $38.5M featuring LundbeckFonden Ventures, Health for Life Capital, Principia SGR, Bristol-Myers Squibb, Seventure Partners, Omnes Capital, and Nestle Health Science
Series E (2020): $52.6M backed by Nestlé Health Science, Health for Life Capital, Takeda Pharmaceutical Company, SymBiosis, LLC, Seventure Partners, Omnes Capital, and Principia
Other Financing Round (2025): $19M with participation from SymBiosis, Seventure Partners, Lundbeckfonden, The Institute for Follicular Lymphoma Innovation, and Primo Capital
Key Investors in Enterome
Lundbeckfond Ventures
Lundbeckfond Ventures is part of the Lundbeck Foundation, a Danish entity focused on biomedical research, particularly in brain research, and operates an international portfolio of venture capital and biotech companies.
Seventure Partners
Seventure Partners is an active investor in innovative companies within digital technologies and life sciences, including health and nutrition, and focuses on addressing environmental challenges through biotechnologies.
Nestlé Health Science
Nestlé Health Science is a leader in nutritional science, committed to redefining health management through a portfolio of science-based consumer health, medical nutrition, and supplement brands.
What's next for Enterome?
With a significant enterprise-level funding history, Enterome is well-positioned for its next phase of growth and clinical development. The recent major strategic investment signals strong investor confidence in the company's platform and therapeutic pipeline. This capital infusion is expected to accelerate the advancement of its drug candidates through clinical trials, further validate its Mimicry platform, and potentially expand its therapeutic indications. Enterome's trajectory suggests a move towards scaling its operations and advancing towards commercialization, aiming to address critical unmet needs in oncology and immunology.
See full Enterome company page
